检索结果 - Yuko Takami
- Showing 1 - 5 results of 5
-
1
-
2
Impact of Anatomical Resection for Hepatocellular Carcinoma With Microportal Invasion (vp1) 由 Masaaki Hidaka, Susumu Eguchi, Koji Okuda, Toru Beppu, Ken Shirabe, Kazuhiro Kondo, Yuko Takami, Masayuki Ohta, Masayuki Shiraishi, Shinichi Ueno, Atsushi Nanashima, Tomoaki Noritomi, Kenji Kitahara, Hikaru Fujioka
出版 2018Artigo -
3
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma 由 Arndt Vogel, Catherine Frenette, Max W. Sung, Bruno Daniele, Ari David Baron, Stephen L. Chan, Jean Frédéric Blanc, Toshiyuki Tamai, Min Ren, Howard J. Lim, Daniel H. Palmer, Yuko Takami, Masatoshi Kudo
出版 2021Artigo -
4
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019 由 Masahito Nakano, Hiroshi Yatsuhashi, Shigemune Bekki, Yuko Takami, Yasuhito Tanaka, Yoko Yoshimaru, Koichi Honda, Yasuji Komorizono, Masaru Harada, Michihiko Shibata, Shotaro Sakisaka, Satoshi Shakado, Kenji Nagata, Tomoharu Yoshizumi, Shinji Itoh, Tetsuro Sohda, Satoshi Oeda, Kazuhiko Nakao, Ryu Sasaki, Tsutomu Yamashita, Akio Ido, Seiichi Mawatari, Makoto Nakamuta, Yoshifusa Aratake, Shuichi Matsumoto, Tatsuji Maeshiro, Takashi Goto, Takuji Torimura
出版 2022Artigo -
5
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analy... 由 Takashi Niizeki, Takayuki Tokunaga, Yuko Takami, Yoshiyuki Wada, Masaru Harada, Michihiko Shibata, Kazuhiko Nakao, Ryu Sasaki, Fumihito Hirai, Satoshi Shakado, Tomoharu Yoshizumi, Shinji Itoh, Hiroshi Yatsuhashi, Shigemune Bekki, Akio Ido, Seiichi Mawatari, Koichi Honda, Rie Sugimoto, Takeshi Senju, Kazuhiro Takahashi, Takuya Kuwashiro, Tatsuji Maeshiro, Makoto Nakamuta, Yoshifusa Aratake, Tsutomu Yamashita, Yuichiro Otsuka, Shuichi Matsumoto, Tetsuro Sohda, Shigeo Shimose, Kenta Murotani, Yasuhito Tanaka
出版 2022Artigo
相关主题
Hepatocellular carcinoma
Medicine
Internal medicine
Gastroenterology
Overall survival
Cancer
Oncology
Propensity score matching
Surgery
Ablation
Ablation Therapy
Adverse effect
Atezolizumab
Bevacizumab
Cancer research
Carcinoma
Chemotherapy
Cirrhosis
Hepatectomy
Hepatology
Immunotherapy
Lenvatinib
Liver function
Microwave ablation
Nuclear medicine
Pembrolizumab
Post-hoc analysis
Prostate cancer
Radiofrequency ablation
Resection